RECARDIO has an experienced management team with longtime and significant experience and reputation in drug development, cardiology, the biotech industry and is complemented by exclusive boards.
Darrell Nix, Ph.D.
Chief Scientific Officer and Head of US Operations
Darrell Nix’s responsibilities span from drug development to scientific affairs management and he is also in charge of US operations.
Darrell was the President and Founder of a Global Drug Development Consulting Group, specializing in difficult ADME issues with small molecule development and large molecule PK/PD modeling. Prior to this he was a key contributor to the successful marketing registration of several oncology compounds as well as other compounds in cardiovascular and metabolic diseases and has more than 25 years of drug discovery and development.
Darrell has a bachelors degree in analytical chemistry and a graduate degree in pharmacology and trained in the US FDA’s Clinical Pharmacology Fellowship program.
Harald Kattnig, MSc.
Vice President Information Systems and Managing Director Austria
Harald Kattnig is Managing Director at our European headquarters at RECARDIO GmbH in Austria. His responsibilities also cover business development and information systems.
Prior to his position he did a pharmaceutical sales training after already working for the company as Director Business Development and Information.
Harald was earlier working at the J. Craig Venter Institute in California and achieved his Masters in Bioinformatics at the University of Northern Iowa, after studying Computer Science at the University of Klagenfurt in Austria.
Colin Minchom, Ph.D.
Vice President of CMC
Colin Minchom is responsible for all aspects of drug development related to the active pharmaceutical ingredient and the formulated drug product.
Prior to joining Recardio, Colin was head of synthetic molecule CMC and global CMC lead for multiple international programs. Colin has held executive positions at international CDMOs. Over his career Colin has contributed to the development with successful commercial launch of more than ten pharmaceutical products.